Fundraising Fox
/Companies
Sign in

Velicept

Malvern, US · Founded 2015 · 5 known investors

Find your way into Velicept

Sign up to find every way you can get introduced to Velicept

  • Your email: who you already know at Velicept, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Velicept team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Biotechnology company developing products for overactive bladder and irritable bowel syndrome.

Biotech

Founders & leadership

DG
Douglas GesslExecutiveExecutive Officer at Alexar Therapeutics
JW
James WalkerExecutiveJames Walker has over 12 years of biopharmaceutical industry experience, including co-founding a drug development startup that achieved FDA engagement within nine months, and directing clinical operations at a private equity-backed drug development fund. He has expertise across oncology, infectious disease, pain management, and other therapeutic areas, with experience in clinical trials spanning multiple continents and drug delivery technologies.

Board

SM
Scott MorensteinBoard director
DH
David HirschBoard director
JB
James BennethumBoard director
ST
Stephen TullmanBoard director

Investors · 5

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · funding news · biocentury.com · Not right? Tell us

Samsara BioCapitalreportedMenlo Park

How we know: funding news · biocentury.com · Not right? Tell us

Also in the syndicate · 2

Becker VenturesCDK

Reported raises · per SEC filings

Form D private placements

$39.9M disclosed across 3 rounds · 2015–2019

▶$6MraisedNov 2019 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott MorensteinDirector
  • Doug GesslExecutive Officer
  • David Hirsch, M.D.Director
  • Jill Becker MastDirector
  • Stephen TullmanDirector
  • Aidan King, MBA, CFADirector
  • Cory S. FreedlandDirector
  • James C. WalkerExecutive Officer, Director
Offering amount
$9.2M
Amount sold
$6M
Minimum investment
$1
Proceeds to insiders
$400K
First sale
Nov 2019
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.5MraisedJul 2018 · 16 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Aidan KingDirector
  • James BennethumDirector
  • Douglas GesslExecutive Officer
  • David HirschDirector
  • Scott MorensteinDirector
  • James WalkerExecutive Officer, Director
  • Cory FreedmanDirector
  • Stephen TullmanDirector
Offering amount
$15.6M
Amount sold
$15.5M
Proceeds to insiders
$850K
First sale
Jul 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$18.4MraisedApr 2017 · 25 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott MorensteinDirector
  • James BennethumDirector
  • Douglas GesslExecutive Officer
  • James WalkerExecutive Officer, Director
  • David HirschDirector
  • Stephen TullmanDirector
Offering amount
$26.3M
Amount sold
$18.4M
Minimum investment
$4.5K
Sales commissions
$1.3M
Proceeds to insiders
$750K
Placement agents
William Blair & Company, MTS Securities, LLC
First sale
Nov 2015
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Velicept Therapeutics Announces FDA Acceptance Of IND Application Of Novel, Once-Daily Formulation Of Solabegron For The Treatment Of Overactive Bladder - BioSpacebiospace.com · Oct 2016

Frequently asked questions

What does Velicept do?
Biotechnology company developing products for overactive bladder and irritable bowel syndrome.
Who are Velicept's investors?
Velicept's investors include Fountain Healthcare Partners, Longitude Capital, Samsara BioCapital.
How much funding has Velicept raised?
Velicept has disclosed $39.9M raised across 3 rounds.
Where is Velicept headquartered?
Velicept is headquartered in Malvern, US.